143 related articles for article (PubMed ID: 22562081)
1. Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis.
Kharfan-Dabaja MA; Pidala J; Kumar A; Terasawa T; Djulbegovic B
Bone Marrow Transplant; 2012 Sep; 47(9):1164-70. PubMed ID: 22562081
[TBL] [Abstract][Full Text] [Related]
2. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.
Kharfan-Dabaja MA; Kumar A; Hamadani M; Stilgenbauer S; Ghia P; Anasetti C; Dreger P; Montserrat E; Perales MA; Alyea EP; Awan FT; Ayala E; Barrientos JC; Brown JR; Castro JE; Furman RR; Gribben J; Hill BT; Mohty M; Moreno C; O'Brien S; Pavletic SZ; Pinilla-Ibarz J; Reddy NM; Sorror M; Bredeson C; Carpenter P; Savani BN
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2117-2125. PubMed ID: 27660167
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens.
Kharfan-Dabaja MA; Bazarbachi A
Cancer Control; 2012 Jan; 19(1):68-75. PubMed ID: 22143063
[TBL] [Abstract][Full Text] [Related]
4. Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha.
Kurosawa S; Yamaguchi H; Yamaguchi T; Fukunaga K; Yui S; Wakita S; Kanamori H; Usuki K; Uoshima N; Yanada M; Shono K; Ueki T; Mizuno I; Yano S; Takeuchi J; Kanda J; Okamura H; Inamoto Y; Inokuchi K; Fukuda T
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1125-1132. PubMed ID: 27040395
[TBL] [Abstract][Full Text] [Related]
5. Markov model of CLL transplants.
Gale RP
Bone Marrow Transplant; 2012 Sep; 47(9):1145-6. PubMed ID: 22948811
[No Abstract] [Full Text] [Related]
6. Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?
Delgado J; Milligan DW; Dreger P
Blood; 2009 Sep; 114(13):2581-8. PubMed ID: 19641189
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
Klyuchnikov E; Bacher U; Kroll T; Shea TC; Lazarus HM; Bredeson C; Fenske TS
Bone Marrow Transplant; 2014 Jan; 49(1):1-7. PubMed ID: 23708703
[TBL] [Abstract][Full Text] [Related]
8. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia.
Hamadani M; Mohty M; Kharfan-Dabaja MA
Cancer Control; 2011 Oct; 18(4):237-45. PubMed ID: 21976242
[TBL] [Abstract][Full Text] [Related]
9. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
Shustov A
Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Promyelocytic Leukemia: Results of a Systematic Review and Meta-Analysis.
Mohty R; Reljic T; Yassine F; Kettaneh C; Al-Husni D; Keller K; Badar T; Murthy H; Foran J; Kumar A; Kharfan-Dabaja MA
Transplant Cell Ther; 2024 Jun; 30(6):599.e1-599.e10. PubMed ID: 38554737
[TBL] [Abstract][Full Text] [Related]
11. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
[TBL] [Abstract][Full Text] [Related]
12. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
14. Stem-cell transplantation in chronic lymphocytic leukemia: the time for designing randomized studies has arrived.
Waselenko JK; Flynn JM; Byrd JC
Semin Oncol; 1999 Feb; 26(1):48-61. PubMed ID: 10073561
[TBL] [Abstract][Full Text] [Related]
15. Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review/meta-analysis.
Kharfan-Dabaja MA; Moukalled N; Reljic T; El-Asmar J; Kumar A
Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):53-64. PubMed ID: 29197550
[TBL] [Abstract][Full Text] [Related]
16. Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review.
Kharfan-Dabaja MA; Reljic T; El-Asmar J; Nishihori T; Ayala E; Hamadani M; Kumar A
Future Oncol; 2016 Nov; 12(22):2631-2642. PubMed ID: 27381652
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.
Hill BT; Ahn KW; Hu ZH; Aljurf M; Beitinjaneh A; Cahn JY; Cerny J; Kharfan-Dabaja MA; Ganguly S; Ghosh N; Grunwald MR; Inamoto Y; Kindwall-Keller T; Nishihori T; Olsson RF; Saad A; Seftel M; Seo S; Szer J; Tallman M; Ustun C; Wiernik PH; Maziarz RT; Kalaycio M; Alyea E; Popat U; Sobecks R; Saber W
Biol Blood Marrow Transplant; 2018 Mar; 24(3):581-586. PubMed ID: 29032274
[TBL] [Abstract][Full Text] [Related]
18. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.
Kharfan-Dabaja MA; Al Malki MM; Deotare U; Raj RV; El-Jurdi N; Majhail N; Cherry MA; Bashir Q; Darrah J; Nishihori T; Sibai H; Hamadani M; de Lima M; Gerds AT; Selby G; Qazilbash MH; Forman SJ; Ayala E; Lipton JH; Hari PN; Muzzafar T; Zhang L; Olteanu H; Perkins J; Sokol L; Kumar A; Ahmed S
Br J Haematol; 2017 Dec; 179(5):781-789. PubMed ID: 28980314
[TBL] [Abstract][Full Text] [Related]
19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.
Kharfan-Dabaja MA; Hamadani M; Reljic T; Nishihori T; Bensinger W; Djulbegovic B; Kumar A
J Hematol Oncol; 2013 Jan; 6():2. PubMed ID: 23289975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
